SCHEMBL23409758

SCHEMBL23409758

Oc1ccccc1SCC1CCCOC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.36
HSD17B10 Q99714 4/20 0.34
HPGD P15428 3/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPK1 P28482 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 2/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
KDM4E B2RXH2 1/20 0.33
KMT2A Q03164 2/20 0.33
FEN1 P39748 1/20 0.32
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23409781 0.91 NAMPT (0.34) NAMPTRAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL77546 0.82 KMT2A (0.40) HSD17B10HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL80348 0.81 ALDH1A1 (0.43) HSD17B10HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL5744003 0.79 CRBN (0.38) HSD17B10HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL23409856 0.73 DDB1 (0.33) HSD17B10HPGDRAB9ANPC1SMN1; SMN2
Oxirane SCHEMBL301351 0.67 P4HB (0.42) HSD17B10HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL23409741 0.67 DDB1 (0.41) HSD17B10HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL2931658 0.66 GBA1 (0.47) SMN1; SMN2NPSR1LMNA
SCHEMBL30049121 0.64 NAMPT (0.65) NAMPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL8746052 0.64 KDM4E (0.48) HSD17B10HPGDRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022249006-A1 USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS AG (CH) 2022-12-01 WO disclosed
US-20220340573-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-10-27 US disclosed
EP-4065228-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS Novartis AG (CH) 2022-10-05 EP disclosed
US-11427586-B2 1,2,4-oxadiazole derivatives as liver X receptor agonists NOVARTIS AG (CH) 2022-08-30 US disclosed
CN-114746149-A 1,2, 4-oxadiazole derivatives as liver X receptor agonists 诺华股份有限公司 2022-07-12 CN disclosed
US-20220064164-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-03-03 US disclosed
WO-2021105857-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS AG (CH) 2021-06-03 WO disclosed
WO-2021105857-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS AG (CH) 2021-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064164-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NR1H4, GPBAR1, NR1I2 NAMPT 3237/4885HSD17B10 206/4885HPGD 216/4885
US-11427586-B2 1,2,4-oxadiazole derivatives as liver X receptor agonists NR1H4, GPBAR1, NR1I2 NAMPT 3237/4885HSD17B10 206/4885HPGD 216/4885
US-20220340573-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NR1H4, GPBAR1, NR1I2 NAMPT 3237/4885HSD17B10 206/4885HPGD 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.